The immediate period after myocardial infarction (MI) represents a unique window of opportunity to encourage patients to quit smoking.
Methods | To our knowledge, the Acute Coronary Treatment and Intervention Outcomes Network Registry is the largest MI registry in the United States; its linkage of patients older than 65 years to Medicare claims has been previously described. 4 Among the 183 783 MI admissions between April 2007 and December 2013, 28 242 patients (15.4%) were current or recent smokers. Patients who died before discharge, were discharged to nursing homes, left against medical advice, or who were not enrolled in Part D were excluded (n = 19 049). Each hospital's institutional review board approved participation in the registry, and the requirement for individual informed consent was waived because data were collected without individual patient identifiers.
Prescription smoking cessation medications (SCMs) included in the study were bupropion and varenicline; nicotine replacement therapies were available over the counter. Early prescription SCM use was defined as filling of a prescription within 90 days postdischarge or supply remaining from a preadmission fill. Duration of SCM use was defined as the time from the first prescription fill to the date of expected end of supply. We assessed patient factors associated with early SCM use using multivariable logistic regression modeling with forward variable selection.
Results | Among the 9193 smoking patients with MI in our cohort, 8942 patients (97%) received smoking cessation counseling during their hospitalization, yet only 647 patients (7.0%) had early-prescription SCM use (bupropion, n = 306 [47.3%] and varenicline, n = 341 [52.7%]). Varenicline use dropped from 12.6% in 2007 to 2.2% in 2013; bupropion use stayed consistently low (2.5% in 2007 and 3.2% in 2013) .
The median durations of use were 6.2 weeks (25th-75th percentiles, 4.3-14.9 weeks) for bupropion and 4.3 weeks (25th-75th percentiles, 4.0-9.0 weeks) for varenicline (P < .001); only 36.7% (n = 55) and 19.7% (n = 57), respectively, filled prescriptions for the typically recommended course of 12 weeks. Within 1 year postdischarge, SCM use only increased to 9.4%. A total of 273 patients (3.0%) were taking a prescription for SCM prior to the index MI; these patients more frequently used prescription SCMs within 1 year post-MI (64.1% [n = 175 of 273] vs 7.7% [n = 690 of 8920]; P < .001).
Early SCM users were more frequently younger, female, and white compared with patients who did not use prescription SCM early post-MI (Table) . In multivariable modeling, race/ ethnicity was no longer a significant variable, and 6 factors remained significantly associated with early SCM use ( Figure) . Each 5-year decrease in age was associated with a 52% (odds ratio [OR], 1.52; 95% CI, 1.38-1.67) greater likelihood of early SCM use. Additionally, patients who were women (OR, 1.46; 95% CI, 1.24-1.71) or who were living in counties with greater than the median high school graduate rate (OR, 1.14; 95% CI, 1.07-1.23) had higher likelihood of early SCM use. Patients with chronic lung disease had a 47% (OR, 1.47; 95% CI, 1.25-1.74) increased likelihood of early SCM use. Patients who underwent in-hospital coronary revascularization (OR, 1.25; 95% CI, 1.02-1.52) and those with peripheral arterial disease (OR, 1.23; 95% CI, 1.01-1.50) also had an approximately 25% higher likelihood of early SCM use.
Discussion | Only 52.8% of patients with MI quit smoking by 1 year after the event, despite the clear benefits of smoking cessation in this population.
5 While pharmacotherapy to assist in cessation efforts is recommended, 6 our study shows very low rates of SCM use post-MI, and this rate has declined over time. Because individuals who successfully quit smoking do so most frequently in the immediate post-MI period, 1 current practices indicate a missed opportunity for smoking cessation and secondary prevention efforts. Limitations of our study include the possibility of residual confounding and lack of data about actual prescription rates, smoking cessation rates post-MI, or reasons for drug prescription or discontinuation.
The results of our study suggest the need for words (smoking cessation counseling rates are high) to be followed by action (SCM use rates can be higher). Patients of older age, male sex, and lower education levels may represent key target populations for more intensive smoking cessation counseling and assistance. Our study also showed shorter duration of use compared with typically recommended courses, which suggests opportunities for further education on adherence to reduce relapses in smoking behavior. (39 285-52 
Association Between Administration of Ticagrelor and Microvascular Endothelial Function
Impaired endothelial function has been associated with an increased risk of adverse cardiovascular events, 1 while ticagrelor use has been associated with reduced risk. Ticagrelor's effect may be partially facilitated via adenosinemediated pleiotropic actions. Ticagrelor stimulates rapid release of adenosine triphosphate from red blood cells, inhibits adenosine uptake, and is associated with increased circulating adenosine levels in patients with acute coronary syndrome. 3 Ticagrelor administration has been shown to augment adenosine-induced coronary blood flow velocity and is associated with improved vascular reactivity compared with clopidogrel. 4 Our study aimed to describe the association between ticagrelor and vascular reactivity in relation to timing of drug administration.
Methods | In this prospective, open-label, clinical trial 5 of 45 participants, we assessed the association of ticagrelor administration with endothelial function and arterial stiffness. The study was approved by Western University Research Ethics Board, and written informed patient consent was obtained. Inclusion criteria were an age of 18 years or older, coronary artery disease with at least 2 cardiovascular risk factors, and abnormal endothelial function defined as a reactive hyperemia index (RHI) of less than 2.0. Exclusion criteria were heart block, bleeding, stroke, dyspnea, valvular heart disease, anticoagulants, treatment with CYP3A4 inhibitors, alcohol or other drug abuse, liver disease, hypersensitivity to the study drug, pregnancy, and latex allergy.
Microvascular endothelial function was determined using a noninvasive assessment of endothelial function (EndoPAT2000; Itamar Medical Inc) as previously described. 6 Plethysmographic probes placed on the index fingers of each hand sense volume changes to measure peripheral arterial tonometry (PAT). The normalized augmentation index (AI75), a measure of arterial stiffness, was calculated from PAT waveforms recorded prior to cuff inflation using the formula (P2−P1)/P1, where P1 is the systolic peak and P2 is the reflected wave peak. The result is normalized to heart rate.
Reactive hyperemia index and AI75 were assessed in the absence of ticagrelor (baseline) and twice following ticagrelor administration for 21 days, at 12 hours after the last dose of ticagrelor (trough), and 2 hours after ticagrelor administration (peak). 
